Advances in Multiple Sclerosis, Volume II

A special issue of Neurology International (ISSN 2035-8377).

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 3511

Special Issue Editor


E-Mail Website
Guest Editor
Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University, 80131 Naples, Italy
Interests: multiple sclerosis; biomarkers; neurorehabilitation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, we have reshaped multiple sclerosis (MS) management thanks to advances in clinical, epidemiological, and biomarker studies. Clinical trials, epidemiological studies, real-world experiences, and case reports have shed light on different aspects of the disease burden and have showed the therapeutic potential (and side effects) of both novel and already existing medications, targeting both disease symptoms and its pathological mechanisms. A number of biomarkers have been developed, tested, and validated in clinical, laboratory, neuroimaging, and neurophysiology studies, including cognitive tests, neuroimmunology measures, and conventional and advanced MRI methods, representing a milestone in better understanding and treating MS. In light of such advances, the costs for MS management are now very much of interest for both national healthcare systems and insurance companies.

This Special Issue aims to contribute to filling knowledge gaps in the MS field. Reviews, full papers, short communications, and case reports are equally welcome, so long as they provide readers with novel insights into MS clinical features, treatments, epidemiology, pharmacoeconomics, and biomarkers (e.g., laboratory, neuroimaging, neurophysiology).

Dr. Marcello Moccia
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Neurology International is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • multiple sclerosis
  • clinical
  • treatment
  • cognition
  • biomarkers
  • neuroimmunology
  • neuroimaging

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Other

15 pages, 512 KiB  
Systematic Review
Altered Cardiac Autonomic Regulation in Individuals with Myasthenia Gravis—A Systematic Review and Meta-Analysis
by Monika Zawadka-Kunikowska, Łukasz Rzepiński, Małgorzata Tafil-Klawe, Nicola Veronese, Mario Barbagallo, Mario Habek and Nils E. Gilhus
Neurol. Int. 2023, 15(3), 1140-1154; https://doi.org/10.3390/neurolint15030071 - 08 Sep 2023
Cited by 2 | Viewed by 1638
Abstract
The aim of this systematic review with meta-analysis was to determine differences in cardiovascular autonomic parameters between patients with myasthenia gravis (MG) and healthy controls (HCs). Two reviewers searched four electronic databases, namely PubMed, Web of Science, EMBASE, and SCOPUS, from database inception [...] Read more.
The aim of this systematic review with meta-analysis was to determine differences in cardiovascular autonomic parameters between patients with myasthenia gravis (MG) and healthy controls (HCs). Two reviewers searched four electronic databases, namely PubMed, Web of Science, EMBASE, and SCOPUS, from database inception to 7 July 2023 for studies investigating cardiovascular autonomic parameters in MG vs. HCs. A random-effects meta-analysis was performed to compute Hedges’ g ± 95% confidence intervals (CI). Out of a total of 2200 records, 8 observational studies with a sample size of 301 patients with MG and 454 HCs were included in the systematic review. Meta-analysis revealed lower values of expiration/inspiration ratio (g = −0.45, I2 = 74.7), baroreflex sensitivity (g = −0.56, 95%CI −0.80, −0.33; I2 = 0.3), percentage of adjacent NN intervals differing by more than 50 ms (g = −1.2, I2 = 82.8), square root of the mean of squared differences between successive beat intervals (g = −1.94, I2 = 95.1), mean of the standard deviations of all NN intervals (g = −0.83, 95%CI −1.37, −0.28; I2 = 55.5), and high frequency of HRV during tilt (g = −0.75, 95%CI −0.11, −0.39; I2 = 0). MG patients vs. HCs had higher systolic blood pressure (g = 0.39; I2 = 56.1), sympathovagal balance at rest/during tilt (LF/HF-RRIsupine, g = 0.44; I2 = 0; LF/HF-RRItilt, g = 0.86; I2 = 0; LF/HFtilt, g = 0.40; I2 = 0). As a group, MG patients have altered cardiac autonomic function, including decreased parasympathetic function, lower baroreflex sensitivity, and higher sympathovagal balance at rest and during orthostatic challenges. Full article
(This article belongs to the Special Issue Advances in Multiple Sclerosis, Volume II)
Show Figures

Figure 1

11 pages, 341 KiB  
Protocol
Social Cognition Impairments in Association to Clinical, Cognitive, Mood, and Fatigue Features in Multiple Sclerosis: A Study Protocol
by Triantafyllos K. Doskas, Foteini Christidi, Kanellos C. Spiliopoulos, Dimitrios Tsiptsios, George D. Vavougios, Anna Tsiakiri, Theofanis Vorvolakos, Christos Kokkotis, Ioannis Iliopoulos, Nikolaos Aggelousis and Konstantinos Vadikolias
Neurol. Int. 2023, 15(3), 1106-1116; https://doi.org/10.3390/neurolint15030068 - 01 Sep 2023
Viewed by 1295
Abstract
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system (CNS), characterized by the diffuse grey and white matter damage. Cognitive impairment (CI) is a frequent clinical feature in patients with MS (PwMS) that can be prevalent even in early [...] Read more.
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system (CNS), characterized by the diffuse grey and white matter damage. Cognitive impairment (CI) is a frequent clinical feature in patients with MS (PwMS) that can be prevalent even in early disease stages, affecting the physical activity and active social participation of PwMS. Limited information is available regarding the influence of MS in social cognition (SC), which may occur independently from the overall neurocognitive dysfunction. In addition, the available information regarding the factors that influence SC in PwMS is limited, e.g., factors such as a patient’s physical disability, different cognitive phenotypes, mood status, fatigue. Considering that SC is an important domain of CI in MS and may contribute to subjects’ social participation and quality of life, we herein conceptualize and present the methodological design of a cross-sectional study in 100 PwMS of different disease subtypes. The study aims (a) to characterize SC impairment in PwMS in the Greek population and (b) to unveil the relationship between clinical symptoms, phenotypes of CI, mood status and fatigue in PwMS and the potential underlying impairment on tasks of SC. Full article
(This article belongs to the Special Issue Advances in Multiple Sclerosis, Volume II)
Back to TopTop